Cargando…

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

BACKGROUND: To evaluate the long-term cost-effectiveness of liraglutide versus sitagliptin or exenatide, added to oral antidiabetic drug mono- or combination therapy respectively, in patients with Type 2 diabetes in Greece. METHODS: The CORE Diabetes Model, a validated computer simulation model, was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tzanetakos, Charalampos, Melidonis, Andreas, Verras, Christos, Kourlaba, Georgia, Maniadakis, Nikos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179852/ https://www.ncbi.nlm.nih.gov/pubmed/25245666 http://dx.doi.org/10.1186/1472-6963-14-419

Ejemplares similares

The disease burden of chronic obstructive pulmonary disease in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Self-reported prevalence of atherothrombosis in a general population sample of adults in Greece; A telephone survey
por: Maniadakis, Nikos, et al.
Publicado: (2011)

Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study
por: Kourlaba, Georgia, et al.
Publicado: (2015)

Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2014)

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece
por: Gourzoulidis, George, et al.
Publicado: (2022)

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece
por: Maniadakis, Nikos, et al.
Publicado: (2013)

Economic evaluation of trimetazidine in the management of chronic stable angina in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2012)

Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2014)

Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2012)

Economic evaluation of alternative assisted reproduction techniques in management of infertility in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2012)

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
por: Kourlaba, Georgia, et al.
Publicado: (2015)

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide
por: DeKoven, Mitch, et al.
Publicado: (2014)

Exenatide: A New Promising Antidiabetic Agent
por: Chakraborti, C. K.
Publicado: (2010)

Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)
por: Yokoyama, Hiroki, et al.
Publicado: (2014)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
por: Mezquita Raya, Pedro, et al.
Publicado: (2013)

Physicians' Perceptions and Adherence to Guidelines for the Management of Hypertension: A National, Multicentre, Prospective Study
por: Theodorou, Mamas, et al.
Publicado: (2012)

Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
por: Voukali, Maria, et al.
Publicado: (2014)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Sivalingam, Suvanjaa, et al.
Publicado: (2021)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery
por: Colbourne, James R. M., et al.
Publicado: (2023)

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
por: Ghetti, Gianni, et al.
Publicado: (2023)

A systematic review of the effectiveness of taxes on nonalcoholic beverages and high-in-fat foods as a means to prevent obesity trends
por: Maniadakis, Nikolaos, et al.
Publicado: (2013)

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
por: Gudipaty, Lalitha, et al.
Publicado: (2014)

Oral cancer treatment costs in Greece and the effect of advanced disease
por: Zavras, Athanasios, et al.
Publicado: (2002)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
por: Pérez, Antonio, et al.
Publicado: (2015)

Effects of antidiabetic drugs on epicardial fat
por: Xourgia, Eleni, et al.
Publicado: (2018)

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
por: Philis-Tsimikas, A, et al.
Publicado: (2013)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
por: Wysham, C, et al.
Publicado: (2011)

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
por: McDonell, Amanda L, et al.
Publicado: (2015)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
por: Gourzoulidis, George, et al.
Publicado: (2023)

Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years
por: Li, Qian, et al.
Publicado: (2018)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m2qgl686ee51sa3gfsekpi8jav